Two different forms of p53 localized differently within cells of urogenital tumours

Cancer Letters

Volumn 144, Issue 1, 1999, Pages 55-64

  Benninghoff, Jens ^a   Kartarius, Sabine ^a   Teleb, Zacharia ^a   Selter, Helga ^a   Unteregger, Gerhard ^a   Zwergel, Thomas ^a   Wullich, Bernd ^a   Montenarh, Mathias ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Growth suppressor; Laser scanning microscopy; p53; Subcellular localization; Western blot

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CARCINOMA; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LASER MICROSCOPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN LOCALIZATION;

BLOTTING, WESTERN; CELL NUCLEOLUS; CELL NUCLEUS; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MALE; MICROSCOPY, CONFOCAL; MUTATION; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0032782070     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00187-1     Document Type: Article

References (64)

1. Addison C., Jenkins J.R., Stürzbecher H.W. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene. 5:1990;423-426.
2. Appel K., Wagner P., Boldyreff B., Issinger O.G., Montenarh M. Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory β-subunit of protein kinase CK2. Oncogene. 11:1995;1971-1978.
3. Ball R.K., Siegl B., Quellhorst S., Brandner G., Braun D.G. Monoclonal antibodies against simian virus 40 nuclear large tumour antigen: epitope mapping, papova virus cross-reaction and cell surface staining. EMBO J. 3:1984;1485-1491.
4. Banks L., Matlashewski G., Crawford L.V. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159:1986;529-534.
5. Bookstein R., MacGrogan D., Hilsenbeck S.G., Sharkey F., Allred D.C. P53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:1993;3369-3373.
6. Borner M.M., Myers C.E., Sartor O., Sei Y., Toko T., Trepel J.B., Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res. 55:1995;2122-2128.
7. Bosari S., Viale G., Bossi P., Maggioni M., Coggi G., Murray J.J., Lee A.K.C. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J. Natl. Cancer Inst. 86:1994;681-687.
8. Bosari S., Viale G., Roncalli M., Graziani D., Borsani G., Lee A.K.C., Coggi G. P53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 147:1995;790-798.
9. Canman C.E., Chen C.Y., Lee M.H., Kastan M.B. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harbor Symp. Quant. Biol. 59:1994;277-286.
10. Castresana J.S., Rubio M.P., Vázquez J.J., Idoate M., Sober A.J., Seizinger B.R., Barnhill R.L. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int. J. Cancer. 55:1993;562-565.
11. Deppert W., Haug M. Evidence for free and metabolically stable p53 protein in nuclear subfractions of simian virus 40-transformed cells. Mol. Cell. Biol. 1986;2233-2240.
12. Dinjens W.N.M., Van der Weiden M.M., Schroeder F.H., Bosman F.T., Trapman J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer. 56:1994;630-633.
13. Dippold W.G., Jay G., DeLeo A., Khoury G., Old L.J. p53 transformation related protein: detection by monoclonal antibody in mouse and human cells. Proc. Natl. Acad. Sci. USA. 78:1981;1695-1699.
14. Eastham J.A., Stapleton A.M.F., Gousse A.E., Timme T.L., Yang G., Slawin K.M., Wheeler T.M., Scardino P.T., Thompson T.C. Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res. 1:1995;1111-1118.
15. Effert P.J., McCoy R.H., Walther P.J., Liu E.T. p53 Gene alterations in human prostate carcinoma. J. Urol. 150:1993;257-261.
16. Effert P.J., Neubauer A., Walther P.J., Liu E.T. Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J. Urol. 147:1992;789-793.
17. Esrig D., Spruck C.H. III, Nichols P.W., Chaiwun B., Steven K., Groshen S., Chen S.C., Skinner D.G., Jones P.A., Cote R.J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 143:1993;1389-1397.
18. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
19. Gannon J.V., Lane D.P. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature. 349:1991;802-806.
20. Ginsberg D., Michael-Michalovitz D., Oren M. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell. Biol. 11:1991;582-585.
21. Götz C., Koenig M.G., Issinger O.G., Montenarh M. A protein kinase CK2 related kinase is tightly associated with SV40 large T antigen. Eur. J. Biochem. 233:1995;327-334.
22. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C.C., Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25:1997;151-157.
23. Hall M.C., Navone N.M., Troncoso P., Pollack A., Zagars G.K., Von Eschenbach A.C., Conti C.J., Chung L.W.K. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology. 45:1995;470-475.
24. Harlow E., Crawford L.V., Pim D.C., Williamson N.M. Monoclonal antibodies specific for the SV40 tumor antigens. J. Virol. 39:1981;861-869.
25. Harris C.C. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis. 17:1996;1187-1198.
26. Heidenberg H.B., Sesterhenn I.A., Gaddipati J.P., Weghorst C.M., Buzard G.S., Moul J.W., Srivastava S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154:1995;414-421.
27. Herrmann C.P.E., Kraiss S., Montenarh M. Association of casein kinase II with immunopurified p53. Oncogene. 6:1991;877-884.
28. Isaacs W.B., Bova G.S., Morton R.A., Bussemakers M.J., Brooks J.D., Ewing C.M. Genetic alterations in prostate cancer. Cold Spring Harbor Symp. Quant. Biol. 59:1994;653-659.
29. Isaacs W.B., Carter B.S., Ewing C.M. Wildtype p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51:1991;4716-4720.
30. Kaighn M.E., Shankar Narayan K., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC3). Invest. Urol. 17:1979;16-23.
31. Knippschild U., Oren M., Deppert W. Abrogation of wildtype p53 mediated growth-inhibition by nuclear exclusion. Oncogene. 12:1996;1755-1765.
32. Lacombe L., Dalbagni G., Zhang Z.F., Cordon-Cardo C., Fair W.R., Herr H.W., Reuter V.E. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: correlation to clinical outcome. J. Clin. Oncol. 14:1996;2646-2652.
33. Mellon K., Thompson S., Charlton R.G., Marsh C., Robinson M., Lane D.P., Harris A.L., Horne C.H.W., Neal D.E. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol. 147:1992;496-499.
34. Milner J.A., Cook A., Sheldon M. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene. 1:1987;453-455.
35. Moll U.M., LaQuaglia M., Bénard J., Riou G. Wildtype p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA. 92:1995;4407-4411.
36. Moll U.M., Ostermeyer A.G., Haladay R., Winkfield B., Frazier M., Zambetti G. Cytoplasmic sequestration of wildtype p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16:1996;1126-1137.
37. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA. 89:1992;7262-7266.
38. Montenarh M. Biochemical, immunological, and functional aspects of the growth suppressor/ oncoprotein p53. Critical Reviews in Oncogenesis. 1992;233-256 CRC Press, Boca Raton.
39. Montenarh M., Kohler M., Henning R. Complex formation of simian virus 40 large T antigen with cellular protein p53. J. Virol. 60:1986;761-764.
40. Moul J.W., Bettencourt M.C., Sesterhenn I.A., Mostofi F.K., McLeod D.G., Srivastava S., Bauer J.J. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery. 120:1996;159-167.
41. Navone N.M., Troncoso P., Pisters L.L., Goodrow T.L., Palmer J.L., Nichols W.W., Von Eschenbach A.C., Conti C.J. P53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85:1993;1657-1669.
42. O'Toole C.M., Povey S., Hepburn P., Franks L.M. Identity of some human bladder cancer cell lines. Nature. 301:1983;429-430.
43. Oberosler P., Hloch P., Ramsperger U., Stahl H. P53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J. 12:1993;2389-2396.
44. Prendergast N.J., Atkins M.R., Schatte E.C., Paulson D.F., Walther P.J. P53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J. Urol. 155:1996;1685-1692.
45. Rotter V., Abutbul H., Ben-Ze'ev A. P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. EMBO J. 2:1983;1041-1047.
46. Rubin S.J., Hailahan D.L., Ashman C.R., Brachman D.G., Beckett M.A., Virudachalam S., Yandell W., Weichselbaum R.R. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J. Surg. Oncol. 46:1991;31-36.
47. Samad A., Carroll R.B. The tumor suppressor p53 is bound to RNA by a stable covalent linkage. Mol. Cell. Biol. 11:1991;1598-1606.
48. Santos M., Butel J.S. Dynamic nature of the association of large tumor antigen and p53 cellular protein with the surfaces of simian virus 40-transformed cells. J. Virol. 49:1984;50-56.
49. Sarkis A.S., Bajorin D.F., Reuter V.E., Herr H.W., Netto G., Zhang Z.F., Schultz P.K., Cordon-Cardo C., Scher H.I. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol. 13:1995;1384-1390.
50. Selter H., Montenarh M. The emerging picture of p53. Int. J. Biochem. 26:1994;145-154.
51. Serth J., Kuczyk M.A., Bokemeyer C., Hervatin C., Nafe R., Tan H.K., Jonas U. P53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br. J. Cancer. 71:1995;201-205.
52. Shaulsky G., Ben-Ze'ev A., Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene. 5:1990;1707-1711.
53. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:1990;6565-6577.
54. Shaulsky G., Goldfinger N., Tosky M.S., Levine A.J., Rotter V. Nuclear location is essential for the activity of p53 protein. Oncogene. 6:1991;2055-2065.
55. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260:1996;623-637.
56. Stattin P., Bergh A., Karlberg L., Nordgren H., Damber J.E. P53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur. Urol. 30:1996;65-72.
57. Sun X.F., Carstensen J.M., Zhang H., Stål O., Wingren S., Hatschek T., Nordenskjöld B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 340:1992;1369-1373.
58. Thompson S.J., Mellon K., Charlton R.G., Marsh C., Robinson M., Neal D.E. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br. J. Urol. 69:1992;609-613.
59. Visakorpi T., Kallioniemi O.P., Heikkinen A., Koivula T., Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst. 84:1992;883-887.
60. Voeller H.J., Sugars L.Y., Pretlow T., Gelmann E.P. P53 oncogene mutations in human prostate cancer specimens. J. Urol. 151:1994;492-495.
61. Wagner P., Appel K., Issinger O.G., Montenarh M. On the interaction of p53 with casein kinase II. Int. J. Oncol. 4:1994;491-498.
62. Watanabe E.R., Tomita Y., Nishiyama T., Tanikawa T., Sato S.S. Correlation of p53 protein expression in human urothelial transitional cell cancers with malignant potential and patient survival. Int. J. Urol. 1:1994;43-48.
63. Weiss J., Heine M., Körner B., Pilch H., Jung E.G. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br. J. Dermatol. 133:1995;23-31.
64. Yenice S., Davis A.T., Goueli S.A., Akdas A., Limas C., Ahmed K. Nuclear casein kinase 2 (CK-2) acitivity in human normal, benign hyperplastic, and cancerous prostate. Prostate. 24:1994;11-16.